论文部分内容阅读
抗肿瘤药物卡培他滨(capecitabine,商品名:Xeloda)的生产商美国罗氏公司通知医师,肾损害患者使用卡培他滨的安全性资料有重要变化。 近期的临床药理学研究评价了癌症患者肾脏损
Roche Corporation, a manufacturer of the anti-cancer drug capecitabine (product name: Xeloda), has informed physicians that significant changes have occurred in the safety profile of patients with renal impairment using capecitabine. Recent clinical pharmacology studies have evaluated kidney damage in cancer patients